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Introduction: Oxidative stress and endothelial damage are involved 
in the development and progression of diabetic nephropathy (DN). In 
this study, we investigated the effects of nitrosonifedipine (NO-NIF) 
having antioxidative property on DN with the endothelial dysfunction.
Patients (or Materials) and Methods: KKAy mice were used as a 
model of developing type II diabetes mellitus with the endothelial 
dysfunction. NO-NIF (30 mg/kg/d) was administrated continuously 
by intraperitoneally injection for 4 weeks. Histologic changes in the 
kidney, urinary protein, urinary albumin, oxidative stress, and blood 
glucose levels were evaluated. Moreover, we also examined whether 
NO-NIF affected the kidney dysfunction in eNOS knockout mice.
Results: In NO-NIF-–treated KKAy mice, the urinary protein and 
albumin were significantly decreased compared with nontreated 
KKAy mice. The pathologic analysis showed expanded glomeru-
lar mesangium in KKAy mice, which was suppressed by NO-NIF 
administration. However, NO-NIF had no effect on blood glucose 
in KKAy mice. NO-NIF decreased dihydroethidium staining in the 
kidney and 8-hydroxy-20-deoxyguanosine in the urine in KKAy mice. 
The expression of intercellular adhesion molecule-1, an endothelial 
cell damage marker, was decreased in the kidney by NO-NIF while 
the podocyte injury marker was not changed. The mRNA expression 
of TNF-α in kidney was also inhibited by NO-NIF. Furthermore, 
the administration of NO-NIF also suppressed the expansion of 
glomerular mesangial area and decreased urinary albumin in eNOS 
knockout mice.
Conclusion: NO-NIF prevents renal dysfunction associated with 
endothelial dysfunction independently of the blood glucose lowering, 
and it might be a potential drug for the prevention of DN.
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Introduction: Few studies have assessed the real-life impact of sec-
ondary prevention drugs on all-cause mortality postmyocardial 
infarction (MI), especially in countries with low incidence of MI. 
The objective of this interim analysis after 3.5-year of follow-up was 
to assess the real-life all-cause mortality impact of drugs reimbursed 
for MI secondary prevention in France: acetylsalicylic acid (ASA), 
antiplatelet agents (APA), beta-blockers (ß-), angiotensin-converting 
enzyme inhibitors (ACEI), statins, and omega-3 supplementation 
(Om3)
Patients (or Materials) and Methods: Cohort study of patients with 
recent (≤3 months) acute MI included by hospital and nonhospital 
cardiologists, with 6-year follow-up. Vital status was obtained from 
the National death registry, and failing that by patient/relatives/physi-
cians investigation. Drug exposure was defined using both physician 
and patient reports at inclusion. Cox proportional hazards model 
was used to estimate for each drug, mortality hazard ratio (HR) of 
exposed versus nonexposed patients, adjusted for gender, age, car-
diovascular risk factors, other MI prevention drugs, and propensity 
score to be exposed at inclusion. Results presented concern an interim 
analysis after 3.5 years of follow-up.
Results: Between May 2006 and June 2009, 596 physicians included 
5538 patients: mean age, 62.1 years, 77.6% male, 9.6% current 
smokers, 14.5% diabetic, 44.6% hypercholesterolemic, 43.6% 
hypertensive, and 8.2% with LVEF < 40%. At inclusion, 97.5% 
were exposed to ASA, 91.0% to APA, 89.7% to ß-, 71.1% to ACEI, 
92.0% to statins, and 15.7% to Om3. The 3.5-year mortality was 
7.8% (95%CI, [7.1%> 8.5%]) with an incidence rate of 23.2 per 
1000 patient-years. Adjusted HR were: 0.98 [0.60–1.61] for ASA, 
0.86 [0.60–1.24] for APA, 0.84 [0.63–1.11] for ß-, 0.80 [0.61–1.03] 
for ACEI, 0.67 [0.45–1.00] for statins, and 0.82 [0.58–1.16] for 
Om3.
Conclusion: The 3.5-year interim all-cause real-life death reduction 
point estimates were close to those of large randomized controlled 
trials, except for ASA, for which almost all patients were exposed. 
The study’s statistical power will be sufficient to confirm or not these 
trends at the final 6-year analysis.
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Introduction: Effective flow through conduit arteries is important 
both for in situ organ perfusion and for tissue function after surgi-
cal and other procedures for revascularization. Membrane-bound, 
calcium-independent phospholipase A2 (iPLA2β ) has been impli-
cated in G-protein coupled receptor-mediated vasoconstriction in 
experimental studies using Sbromoenolactone (S-BEL) as a probe. 
However, the role of iPLA2β is unclear with regard to the regulation 
of vascular tone in humans. S-BEL selectively inhibits iPLA2β . It also 
inhibits other serine hydrolases, including phosphatidate phospho-
hydrolase-1 (PAP-1).
Patients (or Materials) and Methods: We studied human internal 
mammary (IMA) arteries obtained during coronary artery surgery 
and assessed iPLAβ in silico and responses in vitro to S-BEL, its 
enantiomer R-BEL, and propranolol of vessels preconstricted with 
phenylephrine (PE) to 80% of maximum response. All patients were 
undergoing surgery for treatment of ischemic heart disease and gave 
written informed consent to the study, which was approved by the 
local research ethics committee. Data are shown as means and stand-
ard errors. Data were compared by paired (Wilcoxon) or multi-way 
(Friedman) nonparametric tests.
Results: Compared with PE alone, contraction to PE increased dur-
ing incubation of IMA segments in the presence of SBEL 25μ M (PE 
alone, 6.9 [2.4 ] [SE] mN; PE with S-BEL, 12.7 [2.5] mN; P = 0.028, 
Wilcoxon] in contrast to time-dependent decreased contraction to 
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PE during incubation with control solutions (methyl acetate: BEL 
solvent; Krebs buffer or R-BEL; PE alone: 9.8 [2.5] mN; PE with 
controls: 7.1 [2.0] mN: P = 0.012, Wilcoxon). Incubation with S-BEL 
had not effect on contraction to KCl 60 mM compared with incu-
bation with controls (methyl acetate, Krebs buffer, or R-BEL]. The 
post–S-BEL washout contractile response to PE was abolished (PE 
post–S-BEL: -1.2 [0.7] mN; P = 0.002, Friedman test; P = 0.028 vs 
pre–S-BEL PE response). Contraction to PE after washout of con-
trols was similar to initial PE responses. Effects were similar for 
S-BEL 25 uM versus S-BEL 12.5 uM on contractile responses to PE. 
Propranolol (50 mM) prevented contraction to phenylephrine alone 
and the early effect of S-BEL to enhance contractile responses to PE.
Conclusion: S-BEL has complex, biphasic, time-dependent effects 
on PE-mediated arterial constriction. Propranolol is both a beta-
adrenergic antagonist and inhibitor of PAP-1. Although S-BEL selec-
tively inhibits iPLA2β , our findings suggest that other targets may 
also contribute to modulation of PE-dependent arterial contraction.
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Introduction: Hypertension (HBP) is a disease with high morbidity 
and mortality worldwide and is a major etiological factor in heart and 
vascular diseases. An important regulatory mechanism of blood pres-
sure (BP) is the renin angiotensin system (RAS). In fact, all the first-
line drugs for the treatment of hypertension act on some component 
of the RAS. However, these treatments frequently lead to the devel-
opment of changes in morphology and physiology characterized by 
vascular complications. It is therefore necessary to consider adjuvant 
therapies to improve the outcome of treatments and therefore in the 
quality of life of patients with HBP. A therapy that has been shown 
to improve the clinical condition of patients with HBP is hyperbaric 
oxygenation (HBO), in which the patient is subject to a pressure 
of 2 atmospheres absolute with an oxygen concentration of 100%. 
This therapy has been shown to improve vascular smooth muscle 
relaxation, although the mechanism of action has not yet been speci-
fied. The aim of this study is to examine the role of the RAS in the 
relaxation of vessels in hypertensive rats that is produced by HBO.
Patients (or Materials) and Methods: Male Wistar rats were used 
(340 ± 20 g) at standard conditions (light/dark cycle, water and food 
ad libitum), and hypertension was induced by a previously described 
surgical method (PAGE). Stable hypertension was established at 
7 days’ postsurgery (for plethysmographic method). On the eighth 
day, HBO therapy began, and was carried out 5 days per week for 
4 weeks. Rats were sacrificed at the end of treatment, obtaining 
thoracic and abdominal aorta. The endothelium was removed by a 
mechanical method, aortic rings were mounted, and concentration 
response curves were constructed according to increasing doses of 
ANG II for all groups with and without HBO. The results are ana-
lyzed with 2-way ANOVA and post hoc Von Ferroni.
Results: Diastolic pressure was found to be 150 (10) mm Hg, con-
sistent with the definition of hypertension. The angiotesin contractile 
response was lower in the groups of rats treated with HBO, compared 
with the 2 control groups (untreated and SHAM animals).
Conclusion: HBO therapy reduced vascular reactivity in both seg-
ments of the hypertensive rat aorta. This suggests that HBO could 
possibly be used with hypertensive patients to reduce the use of drugs 
in therapy.
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Introduction: Congestive heart failure (CHF), caused by ischemic 
cardiomyophaty and diabetes II-type, is a devastating clinical prob-
lem.The aim of this study was highlight several advances in the under-
standing of molecular pathways involved in cardiac hypertrophy, 
inflammatory signaling, and oxidant stress that may play a key role 
in altering transcriptional regulatory networks regulating adapta-
tion or maladaptation, and consequently, the transition to overt HF.
Patients (or Materials) and Methods: A total of 56 patients aged 
53 (6) years, with ischemic cardiomyophaties (ICMP) accompanied 
with the diabetes II-type were included in the study. Entry criteria’s 
were: the left ventricular ejection fraction (LVEF) < 40% and mild 
LV dilatation, symptoms of CHF for the last 2 months, at least. All 
patients including in the study were randomized into 2 groups; con-
trol received standard therapy (digoxin 0.025 mg per day, inhibitor 
of ACE and a diuretic, n = 29) and the main one (n = 30) an inhibitor 
of ACE, a diuretic, and Adenocin (2 ampoules diluted in 50-100 mL 
of saline in infused IV). There were no significant differences in base-
line characteristics (demographic and anamnesis) between groups. 
Plasma levels of cytokines (interleukine-1β [L-1β ], tumor necrosis 
factor [TNF-a]), redox-potential NAD/NADH, superoxide anion 
production, activities of superoxide dismutase (SOD), and catalase 
(CT) were determined.
Results: It has been shown that in the control group, the functional 
class (FC) of CHF by NYHA decreased by 12%, the dyspnea by 
49%, lung congestion by 78%, hepatomegaly by 70%, and periph-
eral edema improved by 45%. The total CHF score improved by 
52%. In the main group, the FC of CHF improved by 25%, dyspnea 
and lung congestion disappeared completely, hepatomegaly improved 
by 74%, peripheral edema -by 88%. The total score improved by 
67%. In the group receiving Adenocin, LVEF improved by 16% 
(from 26% to 42%), stroke volume improved by 28%. Hence, the 
optimal treatment of CHF would be achieved through increase in the 
energy supply: redox-potential NAD/NADH increased by 34%, the 
content of pyridine nucleotide in the plasma by 40%. The activity of 
the marker of hyperactivation of the system of reactive oxygen pro-
duction decreased by 48% and activities of SOD and CT increased 
by 45% and 60%, respectively. Treatment with Adenocin leads to a 
markedly improve of the state of immune system and as a result the 
content of proinflammatory cytokines, IL-1 β and TNF-a decreased 
by 49 and 38%, respectively.
Conclusion: The modern approach to treatment of HF is multidis-
ciplinary, given that mandatory multiorgan attention is required to 
ensure early good outcome in these high-risk patients with ICMP 
and diabetes II-type. From the present results, it is evident that 
Adenocin cessates cardiac remodeling during the development of 
cardiac hypertrophy and resrores functional activity of the myo-
cardium.
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